Literature DB >> 9065199

Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules.

A Konijnenberg1, E W Stokkers, J A van der Post, M C Schaap, K Boer, O P Bleker, A Sturk.   

Abstract

OBJECTIVES: Platelets play an important role in the pathophysiologic mechanisms of preeclampsia. Our purpose was to investigate by means of flow cytometry to what extent platelets circulate in an activated state during normal pregnancy and whether this activation is more extensive in preeclampsia. STUDY
DESIGN: Platelets in whole blood from 10 preeclamptic third-trimester pregnant women (highest diastolic blood pressure range 100 to 130 mm Hg, proteinuria range 0.59 to 11.5 gm/24 hr) and from 10 normotensive third-trimester pregnant controls were analyzed with the following activation markers: anti-P-selectin (alpha-granule secretion), anti-CD63 (lysosomal secretion), PAC-1 (monoclonal antibody against fibrinogen receptor conformation of the glycoprotein IIb/IIIa complex), anti-platelet endothelial cell adhesion molecule-1, and annexin-V (a placental protein that binds to negatively charged phospholipids, present on the outside of the platelet plasma membrane after activation). The differences in surface antigen exposure between the two groups were determined by double-label flow cytometry. Flow cytometric data were analyzed in two ways: first, the percentages of activated platelets above a certain threshold compared with a nonpregnant control sample were determined, indicative for activation of a subpopulation of cells, and, second, the mean fluorescence intensities were determined, indicative of the mean surface antigen expression of the total platelet population.
RESULTS: Analysis of the percentage of activated platelets proved most informative. With this analysis an enhanced platelet activation status was present in 4 of 10 normotensive patients and a more extensive platelet activation status in all 10 preeclamptic patients, as indicated by P-selectin (p = 0.008) and CD63 (p = 0.03) expression. Increased platelet endothelial cell adhesion molecule-1 (p = 0.005) expression was also observed in preeclampsia.
CONCLUSIONS: Flow cytometric analysis clearly indicated that platelets circulate in a more extensively activated state during preeclampsia than during normal pregnancy. The increased platelet endothelial cell adhesion molecule-1 expression in preeclamptic patients demonstrates that, besides alpha-granular and lysosomal release, other hitherto unknown mechanisms are involved. Platelet endothelial cell adhesion molecule-1 appears to be the best marker to distinguish preeclamptic patients from normotensive pregnant women. Only a subpopulation of the platelets appears to be activated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9065199     DOI: 10.1016/s0002-9378(97)70516-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  Physiological changes in hematological parameters during pregnancy.

Authors:  Surabhi Chandra; Anil Kumar Tripathi; Sanjay Mishra; Mohammad Amzarul; Arvind Kumar Vaish
Journal:  Indian J Hematol Blood Transfus       Date:  2012-07-15       Impact factor: 0.900

2.  Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia.

Authors:  Yuping Wang; David F Lewis; Yang Gu; Shuang Zhao; Lynn J Groome
Journal:  Hypertension       Date:  2010-12-20       Impact factor: 10.190

3.  Integration of metabolomic and transcriptomic networks in pregnant women reveals biological pathways and predictive signatures associated with preeclampsia.

Authors:  Rachel S Kelly; Damien C Croteau-Chonka; Amber Dahlin; Hooman Mirzakhani; Ann C Wu; Emily S Wan; Michael J McGeachie; Weiliang Qiu; Joanne E Sordillo; Amal Al-Garawi; Kathryn J Gray; Thomas F McElrath; Vincent J Carey; Clary B Clish; Augusto A Litonjua; Scott T Weiss; Jessica A Lasky-Su
Journal:  Metabolomics       Date:  2016-12-12       Impact factor: 4.290

4.  Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial.

Authors:  Lauren H Theilen; Heather D Campbell; Sunni L Mumford; Alexandra C Purdue-Smithe; Lindsey A Sjaarda; Neil J Perkins; Jeannie G Radoc; Robert M Silver; Enrique F Schisterman
Journal:  Am J Obstet Gynecol       Date:  2020-05-17       Impact factor: 8.661

5.  Premature labor: a state of platelet activation?

Authors:  Offer Erez; Roberto Romero; Debra Hoppensteadt; Jawed Fareed; Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Nandor Gabor Than; Edi Vaisbuch; Chong Jai Kim; Jimmy Espinoza; Pooja Mittal; Neil Hamill; Chia-Ling Nhan-Chang; Moshe Mazor; Sonia Hassan
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

Review 6.  Vascular and cellular calcium in normal and hypertensive pregnancy.

Authors:  Zuzana Adamova; Sifa Ozkan; Raouf A Khalil
Journal:  Curr Clin Pharmacol       Date:  2009-09-01

Review 7.  The nitric oxide pathway and possible therapeutic options in pre-eclampsia.

Authors:  Tamanrit Johal; Christoph C Lees; Thomas R Everett; Ian B Wilkinson
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

8.  Proteomics and Metabolomics Profiling of Platelets and Plasma Mediators of Thrombo-Inflammation in Gestational Hypertension and Preeclampsia.

Authors:  Luiz Gustavo N de Almeida; Daniel Young; Lorraine Chow; Joshua Nicholas; Adrienne Lee; Man-Chiu Poon; Antoine Dufour; Ejaife O Agbani
Journal:  Cells       Date:  2022-04-07       Impact factor: 7.666

Review 9.  Potential markers of preeclampsia--a review.

Authors:  Simon Grill; Corinne Rusterholz; Rosanna Zanetti-Dällenbach; Sevgi Tercanli; Wolfgang Holzgreve; Sinuhe Hahn; Olav Lapaire
Journal:  Reprod Biol Endocrinol       Date:  2009-07-14       Impact factor: 5.211

Review 10.  Combined Screening for Early Detection of Pre-Eclampsia.

Authors:  Hee Jin Park; Sung Shin Shim; Dong Hyun Cha
Journal:  Int J Mol Sci       Date:  2015-08-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.